Brandon Biocatalyst

Respirion Pharmaceuticals is an early-stage biotechnology company established in 2018 that specializes in developing innovative treatments for respiratory diseases, particularly Cystic Fibrosis. Originating as a spinout from the Telethon Kids Institute in Perth, the company has focused on creating an inhaled therapy that combines the antibiotic tobramycin with an adjuvant designed to disrupt bacterial biofilms in the lungs. This approach aims to enhance the efficacy of antibiotics and improve patient outcomes in combating lung infections associated with Cystic Fibrosis. The company's lead product has demonstrated promising results in initial clinical trials, which were conducted in collaboration with the Western Australian Department of Health. To advance its research and clinical trials further, Respirion has formed partnerships with prominent organizations, including Australia’s Medical Research Commercialisation Fund and the US Cystic Fibrosis Foundation.

Currus Biologics is a biotechnology company focused on developing CAR-T cell therapies aimed at treating solid tumors. The company specializes in creating bispecific antigen-presenting and T-cell engagers to target various cancers, including breast, colon, pancreatic, and prostate cancers. By innovating chimeric antigen receptors, Currus Biologics seeks to enhance the efficacy of cancer treatments, enabling patients with solid tumor indications to receive more effective therapies.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.

Cincera Therapeutics Pty Ltd is a privately held biotechnology company based in Mawson Lakes, Australia, established in 2017. The company specializes in the discovery and development of small molecule drugs aimed at treating challenging inflammatory and fibrotic conditions linked to obesity, metabolic disorders, and cancer. Cincera's innovative approach focuses on creating effective therapies that address difficult-to-treat diseases, including applications for liver problems and other related health issues, ultimately enabling healthcare providers to improve patient outcomes.

OccuRx is a Melbourne-based biopharmaceutical company founded in 2014, focusing on the development of innovative therapeutic strategies for ophthalmic disorders linked to retinal fibrosis. The company aims to address the unmet clinical need for targeted ocular therapies through its proprietary small-molecule drugs, which are designed to enhance visual acuity and prevent vision loss in inflammatory and degenerative eye diseases. OccuRx's strategies enable healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce inflammation in the retina, thereby improving patient outcomes in the treatment of these conditions.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a primary cause of dry eye disease (DED). The company's portfolio includes a range of compounds designed to address the underlying causes of MGD and improve health outcomes for individuals suffering from ocular surface diseases, where effective treatment options are limited. Azura utilizes a novel drug delivery platform to enhance the efficacy of its therapies. The company is headquartered in Tel Aviv-Yafo, Israel, with operational presence in Australia and the United States, and is supported by a management team experienced in the development and commercialization of novel ocular treatments.

Denteric is focused on developing vaccines to combat periodontal diseases, leveraging research from the University of Melbourne and collaboration with CSL Limited. The company's biotechnology platform targets the virulence factors produced by the bacterium Porphyromonas gingivalis and related species, which are known to cause various dental diseases and their complications. By creating these vaccines, Denteric aims to provide effective treatments for patients suffering from dental issues, improving their overall oral health. The company has secured funding that is distributed in three parts annually from 2019 to 2021, supporting its ongoing research and development efforts.

George Medicines is a drug manufacturing company that improves the management of non-communicable diseases.

OccuRx is a Melbourne-based biopharmaceutical company founded in 2014, focusing on the development of innovative therapeutic strategies for ophthalmic disorders linked to retinal fibrosis. The company aims to address the unmet clinical need for targeted ocular therapies through its proprietary small-molecule drugs, which are designed to enhance visual acuity and prevent vision loss in inflammatory and degenerative eye diseases. OccuRx's strategies enable healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce inflammation in the retina, thereby improving patient outcomes in the treatment of these conditions.